Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 20;12(5):101567.
doi: 10.1016/j.gendis.2025.101567. eCollection 2025 Sep.

The biological roles and molecular mechanisms of m6A reader IGF2BP1 in the hallmarks of cancer

Affiliations
Review

The biological roles and molecular mechanisms of m6A reader IGF2BP1 in the hallmarks of cancer

Li Qiu et al. Genes Dis. .

Abstract

N6-methyladenosine (m6A) is the most abundant and well-investigated internal RNA modification in eukaryotic RNAs, affecting its target gene expression by controlling RNA localization, splicing, stability, and translation. m6A modifications are regulated by m6A methyltransferase complex, demethylase, and reading proteins. Insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1), a member of a conserved family of single-stranded RNA-binding proteins, has recently been identified as a vital m6A reading protein. IGF2BP1 is highly expressed in various tumors and is associated with poor prognosis and treatment resistance. Furthermore, previous studies have shown that IGF2BP1 plays critical roles in regulating various cancer hallmarks, including sustained cell proliferation, cell death resistance, activation of invasion and metastasis, deregulated cellular energetics, immune evasion, and unlocking phenotypic plasticity. IGF2BP1 could promote the expression of cancer-related genes by recognizing their m6A sites, thereby altering cell characteristics, and eventually, malignancy. Therefore, IGF2BP1 might be a potential target for tumor diagnosis and anti-tumor therapeutic strategies. This review summarizes the current knowledge on the functional roles and underlying molecular mechanisms of IGF2BP1 in regulating cancer hallmarks. Moreover, we discuss the prospects of IGF2BP1 as a potential tumor diagnosis marker, as well as a potential target for an anti-tumor therapeutic strategy.

Keywords: Cancer hallmarks; IGF2BP1; Molecular therapy; m6A modification reader.

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflict of interests.

Figures

Figure 1
Figure 1
Working model of m6A regulator (writers, erasers, and readers) on m6A modification.
Figure 2
Figure 2
Regulation of IGF2BP1 on mRNA stability and mRNA translation. (A) Domain structure of IGF2BP1. IGF2BP1 contains two RRM domains (orange) and four KH domains (red). (B) IGF2BP1 binds to target mRNAs and RNA-binding proteins (RBPs) in the cytoplasm to regulate mRNA transport, stability, and translation by recruiting transcripts into protective messenger ribonucleoprotein particles (mRNPs).
Figure 3
Figure 3
IGF2BP1's regulation on cancer's hallmarks. IGF2BP1 mainly regulates six cancer hallmarks, including sustained cell proliferation, cell death resistance, activation of invasion and metastasis, deregulated cellular energetics, immune evasion, and unlocking phenotypic plasticity.

Similar articles

References

    1. Martinez C.A., Marteinsdottir I., Josefsson A., Sydsjö G., Theodorsson E., Rodriguez-Martinez H. Epigenetic modifications appear in the human placenta following anxiety and depression during pregnancy. Placenta. 2023;140:72–79. - PubMed
    1. Lin L., Hu M., Li Q., et al. Oleic acid availability impacts thymocyte preprogramming and subsequent peripheral Treg cell differentiation. Nat Immunol. 2024;25(1):54–65. - PMC - PubMed
    1. Wu Z., Zhang W., Qu J., Liu G.H. Emerging epigenetic insights into aging mechanisms and interventions. Trends Pharmacol Sci. 2024;45(2):157–172. - PubMed
    1. Jeong S., Chokkalla A.K., Davis C.K., Vemuganti R. Post-stroke depression: epigenetic and epitranscriptomic modifications and their interplay with gut microbiota. Mol Psychiatr. 2023;28(10):4044–4055. - PMC - PubMed
    1. Gao X., Huang X., Wang Y., et al. Global research hotspots and frontier trends of epigenetic modifications in autoimmune diseases: a bibliometric analysis from 2012 to 2022. Medicine (Baltim) 2023;102(39) - PMC - PubMed

LinkOut - more resources